The clinical development strategy in oncology during the last decade has been substantially affected in several ways by the advent of immunotherapy1, and more recently, cell and gene therapy2 treatment options.
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
